世界の腫瘍壊死因子阻害剤市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV12765)
◆英語タイトル:Global Tumor Necrosis Factor Inhibitors Market Insights and Forecast to 2026
◆商品コード:QYR20NV12765
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:118
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは腫瘍壊死因子阻害剤の世界市場について調査・分析した資料です。種類別(ヒュミラ、エンブレル、レミケード、その他)の市場規模、用途別(アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別腫瘍壊死因子阻害剤の競争状況、市場シェア
・世界の腫瘍壊死因子阻害剤市場:種類別市場規模 2015年-2020年(ヒュミラ、エンブレル、レミケード、その他)
・世界の腫瘍壊死因子阻害剤市場:種類別市場規模予測 2021年-2026年(ヒュミラ、エンブレル、レミケード、その他)
・世界の腫瘍壊死因子阻害剤市場:用途別市場規模 2015年-2020年(アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他)
・世界の腫瘍壊死因子阻害剤市場:用途別市場規模予測 2021年-2026年(アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他)
・北米の腫瘍壊死因子阻害剤市場分析:米国、カナダ
・ヨーロッパの腫瘍壊死因子阻害剤市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの腫瘍壊死因子阻害剤市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の腫瘍壊死因子阻害剤市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの腫瘍壊死因子阻害剤市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):EPIRUS Biopharmaceuticals、Bionovis、CASI Pharmaceuticals、Janssen Biotech、Momenta Pharmaceuticals、GlaxoSmithKline、HanAll Biopharma、Intas Pharmaceuticals、LEO Pharma、Dexa Medica、LG Life Sciences、MedImmune
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Market
The global Tumor Necrosis Factor Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Tumor Necrosis Factor Inhibitors Scope and Market Size
Tumor Necrosis Factor Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Necrosis Factor Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Tumor Necrosis Factor Inhibitors market is segmented into
Humira
Enbrel
Remicade
Others

Segment by Application, the Tumor Necrosis Factor Inhibitors market is segmented into
Alzheimer’s Diseases
Parkinson’s Diseases
Ischemic Stroke
Multiple Sclerosis
Others

Regional and Country-level Analysis
The Tumor Necrosis Factor Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the Tumor Necrosis Factor Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Tumor Necrosis Factor Inhibitors Market Share Analysis
Tumor Necrosis Factor Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Tumor Necrosis Factor Inhibitors business, the date to enter into the Tumor Necrosis Factor Inhibitors market, Tumor Necrosis Factor Inhibitors product introduction, recent developments, etc.

The major vendors covered:
EPIRUS Biopharmaceuticals
Bionovis
CASI Pharmaceuticals
Janssen Biotech
Momenta Pharmaceuticals
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
Dexa Medica
LG Life Sciences
MedImmune

【レポートの目次】

1 Study Coverage
1.1 Tumor Necrosis Factor Inhibitors Product Introduction
1.2 Market Segments
1.3 Key Tumor Necrosis Factor Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Type
1.4.2 Humira
1.4.3 Enbrel
1.4.4 Remicade
1.4.5 Others
1.5 Market by Application
1.5.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Application
1.5.2 Alzheimer’s Diseases
1.5.3 Parkinson’s Diseases
1.5.4 Ischemic Stroke
1.5.5 Multiple Sclerosis
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Tumor Necrosis Factor Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global Tumor Necrosis Factor Inhibitors Revenue 2015-2026
2.1.2 Global Tumor Necrosis Factor Inhibitors Sales 2015-2026
2.2 Global Tumor Necrosis Factor Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Tumor Necrosis Factor Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Tumor Necrosis Factor Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Tumor Necrosis Factor Inhibitors Competitor Landscape by Players
3.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers
3.1.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers
3.2.1 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Tumor Necrosis Factor Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Revenue in 2019
3.2.5 Global Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Tumor Necrosis Factor Inhibitors Price by Manufacturers
3.4 Tumor Necrosis Factor Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 Tumor Necrosis Factor Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Tumor Necrosis Factor Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Tumor Necrosis Factor Inhibitors Market Size by Type (2015-2020)
4.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020)
4.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type (2015-2020)
4.1.3 Tumor Necrosis Factor Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Tumor Necrosis Factor Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Tumor Necrosis Factor Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Tumor Necrosis Factor Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Tumor Necrosis Factor Inhibitors Market Size by Application (2015-2020)
5.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020)
5.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application (2015-2020)
5.1.3 Tumor Necrosis Factor Inhibitors Price by Application (2015-2020)
5.2 Tumor Necrosis Factor Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Tumor Necrosis Factor Inhibitors Price Forecast by Application (2021-2026)

6 North America
6.1 North America Tumor Necrosis Factor Inhibitors by Country
6.1.1 North America Tumor Necrosis Factor Inhibitors Sales by Country
6.1.2 North America Tumor Necrosis Factor Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
6.3 North America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

7 Europe
7.1 Europe Tumor Necrosis Factor Inhibitors by Country
7.1.1 Europe Tumor Necrosis Factor Inhibitors Sales by Country
7.1.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
7.3 Europe Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Tumor Necrosis Factor Inhibitors by Region
8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region
8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

9 Latin America
9.1 Latin America Tumor Necrosis Factor Inhibitors by Country
9.1.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Country
9.1.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
9.3 Central & South America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors by Country
10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country
10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

11 Company Profiles
11.1 EPIRUS Biopharmaceuticals
11.1.1 EPIRUS Biopharmaceuticals Corporation Information
11.1.2 EPIRUS Biopharmaceuticals Description and Business Overview
11.1.3 EPIRUS Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.1.5 EPIRUS Biopharmaceuticals Related Developments
11.2 Bionovis
11.2.1 Bionovis Corporation Information
11.2.2 Bionovis Description and Business Overview
11.2.3 Bionovis Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bionovis Tumor Necrosis Factor Inhibitors Products Offered
11.2.5 Bionovis Related Developments
11.3 CASI Pharmaceuticals
11.3.1 CASI Pharmaceuticals Corporation Information
11.3.2 CASI Pharmaceuticals Description and Business Overview
11.3.3 CASI Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.3.5 CASI Pharmaceuticals Related Developments
11.4 Janssen Biotech
11.4.1 Janssen Biotech Corporation Information
11.4.2 Janssen Biotech Description and Business Overview
11.4.3 Janssen Biotech Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Products Offered
11.4.5 Janssen Biotech Related Developments
11.5 Momenta Pharmaceuticals
11.5.1 Momenta Pharmaceuticals Corporation Information
11.5.2 Momenta Pharmaceuticals Description and Business Overview
11.5.3 Momenta Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.5.5 Momenta Pharmaceuticals Related Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Corporation Information
11.6.2 GlaxoSmithKline Description and Business Overview
11.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Products Offered
11.6.5 GlaxoSmithKline Related Developments
11.7 HanAll Biopharma
11.7.1 HanAll Biopharma Corporation Information
11.7.2 HanAll Biopharma Description and Business Overview
11.7.3 HanAll Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Products Offered
11.7.5 HanAll Biopharma Related Developments
11.8 Intas Pharmaceuticals
11.8.1 Intas Pharmaceuticals Corporation Information
11.8.2 Intas Pharmaceuticals Description and Business Overview
11.8.3 Intas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.8.5 Intas Pharmaceuticals Related Developments
11.9 LEO Pharma
11.9.1 LEO Pharma Corporation Information
11.9.2 LEO Pharma Description and Business Overview
11.9.3 LEO Pharma Sales, Revenue and Gross Margin (2015-2020)
11.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Products Offered
11.9.5 LEO Pharma Related Developments
11.10 Dexa Medica
11.10.1 Dexa Medica Corporation Information
11.10.2 Dexa Medica Description and Business Overview
11.10.3 Dexa Medica Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Products Offered
11.10.5 Dexa Medica Related Developments
11.1 EPIRUS Biopharmaceuticals
11.1.1 EPIRUS Biopharmaceuticals Corporation Information
11.1.2 EPIRUS Biopharmaceuticals Description and Business Overview
11.1.3 EPIRUS Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.1.5 EPIRUS Biopharmaceuticals Related Developments
11.12 MedImmune
11.12.1 MedImmune Corporation Information
11.12.2 MedImmune Description and Business Overview
11.12.3 MedImmune Sales, Revenue and Gross Margin (2015-2020)
11.12.4 MedImmune Products Offered
11.12.5 MedImmune Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Tumor Necrosis Factor Inhibitors Market Estimates and Projections by Region
12.1.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Tumor Necrosis Factor Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Tumor Necrosis Factor Inhibitors Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Tumor Necrosis Factor Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

...

【掲載企業】

EPIRUS Biopharmaceuticals、Bionovis、CASI Pharmaceuticals、Janssen Biotech、Momenta Pharmaceuticals、GlaxoSmithKline、HanAll Biopharma、Intas Pharmaceuticals、LEO Pharma、Dexa Medica、LG Life Sciences、MedImmune

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の腫瘍壊死因子阻害剤市場2026:インサイト・予測(Global Tumor Necrosis Factor Inhibitors Market Insights and Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。